FDA inspection
Wyeth Parenterals Divison of Wyeth Holdings Corp.: FDA inspection ending May 26, 2006
FDA inspection 428948 · Voluntary Action Indicated (VAI) · Carolina, PR
Key facts
| Inspection ID | 428948 |
|---|---|
| Firm | Wyeth Parenterals Divison of Wyeth Holdings Corp. |
| FEI number | 2650060 |
| Address | 8700 Ave 65 Infanteria 97 |
| City | Carolina |
| State | PR |
| ZIP | 00987-7627 |
| Fiscal year | 2006 |
| Inspection end date | May 26, 2006 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data